JP2020524157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524157A5 JP2020524157A5 JP2019570112A JP2019570112A JP2020524157A5 JP 2020524157 A5 JP2020524157 A5 JP 2020524157A5 JP 2019570112 A JP2019570112 A JP 2019570112A JP 2019570112 A JP2019570112 A JP 2019570112A JP 2020524157 A5 JP2020524157 A5 JP 2020524157A5
- Authority
- JP
- Japan
- Prior art keywords
- immune checkpoint
- pharmaceutical composition
- inhibitor
- histone methyltransferase
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127173A JP2023162213A (ja) | 2017-06-20 | 2023-08-03 | がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305755 | 2017-06-20 | ||
| EP17305755.5 | 2017-06-20 | ||
| PCT/EP2018/066383 WO2018234367A1 (en) | 2017-06-20 | 2018-06-20 | SUV39H1 HISTONE METHYLTRANSFERASE INHIBITOR FOR USE IN ANTICANCER POLYTHERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127173A Division JP2023162213A (ja) | 2017-06-20 | 2023-08-03 | がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524157A JP2020524157A (ja) | 2020-08-13 |
| JP2020524157A5 true JP2020524157A5 (enExample) | 2021-07-29 |
Family
ID=59285119
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570112A Pending JP2020524157A (ja) | 2017-06-20 | 2018-06-20 | がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤 |
| JP2023127173A Pending JP2023162213A (ja) | 2017-06-20 | 2023-08-03 | がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127173A Pending JP2023162213A (ja) | 2017-06-20 | 2023-08-03 | がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20200147099A1 (enExample) |
| EP (1) | EP3641739A1 (enExample) |
| JP (2) | JP2020524157A (enExample) |
| CN (1) | CN111032025A (enExample) |
| WO (1) | WO2018234367A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| US12396996B2 (en) | 2019-08-06 | 2025-08-26 | The General Hospital Corporation | Compounds, pharmaceutical compositions, and methods of their use in reversing cancer chemoresistance |
| CN117487012A (zh) * | 2019-08-13 | 2024-02-02 | 东北泰克诺亚奇股份有限公司 | 用于抑制纤维粘连蛋白与lilrb4的结合的抗lilrb4抗体或其衍生物 |
| US11760802B2 (en) | 2019-12-19 | 2023-09-19 | Ngm Biopharmaceuticals, Inc. | ILT3-binding agents and methods of use thereof |
| TW202216768A (zh) | 2020-06-22 | 2022-05-01 | 美商恩格姆生物製藥公司 | Ｌａｉｒ－１結合劑及其使用方法 |
| WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| CN115060902B (zh) * | 2022-05-13 | 2025-07-11 | 上海市第十人民医院 | 可作为肿瘤诊断和预后分析标志物的cGAS甲基化修饰及其检测试剂和应用 |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| CN116790664A (zh) * | 2023-05-31 | 2023-09-22 | 新乡医学院 | 敲低suv39h1表达的cho细胞系的应用、重组蛋白表达系统 |
| EP4520334A1 (en) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010033920A2 (en) * | 2008-09-19 | 2010-03-25 | Whitehead Institute For Biomedical Research | Compositions and methods for enhancing cell reprogramming |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| HUE040213T2 (hu) | 2010-06-11 | 2019-02-28 | Kyowa Hakko Kirin Co Ltd | Anti-TIM antitest |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013192274A2 (en) * | 2012-06-19 | 2013-12-27 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| JP6465803B2 (ja) | 2012-10-22 | 2019-02-06 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | Ｅｔｐ誘導体 |
| US9675571B2 (en) | 2013-03-15 | 2017-06-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (IDO) |
| WO2015035112A1 (en) | 2013-09-05 | 2015-03-12 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
| EP3733188B1 (en) * | 2015-06-08 | 2023-01-25 | The Regents of the University of California | Use of h3k9me3 modulation for enhancing cognitive function |
-
2018
- 2018-06-20 JP JP2019570112A patent/JP2020524157A/ja active Pending
- 2018-06-20 EP EP18733569.0A patent/EP3641739A1/en active Pending
- 2018-06-20 WO PCT/EP2018/066383 patent/WO2018234367A1/en not_active Ceased
- 2018-06-20 US US16/624,977 patent/US20200147099A1/en not_active Abandoned
- 2018-06-20 CN CN201880054127.8A patent/CN111032025A/zh active Pending
-
2020
- 2020-01-27 US US16/773,192 patent/US20200157225A1/en not_active Abandoned
-
2023
- 2023-08-03 JP JP2023127173A patent/JP2023162213A/ja active Pending
-
2024
- 2024-03-19 US US18/609,709 patent/US20240216388A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524157A5 (enExample) | ||
| US20240216388A1 (en) | Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy | |
| Andersch et al. | CD171-and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing | |
| KR102763121B1 (ko) | 치료적 면역 세포의 효능의 향상 방법 | |
| JP2018518939A5 (enExample) | ||
| JP7433348B2 (ja) | キメラポリペプチド及びそれらの細胞膜における局在を変更する方法 | |
| Collin | Immune checkpoint inhibitors: a patent review (2010-2015) | |
| IL277398B1 (en) | Pd-l1 binding affimers, and uses related thereto | |
| JP2019508444A5 (enExample) | ||
| HRP20240510T1 (hr) | Kombinacija modulatora imunosne kontrolne točke i kompleksa koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za uporabu u medicini | |
| HRP20201756T1 (hr) | Antitijela koja sadrže modificirane regije teškog lanca | |
| JP2018503399A5 (enExample) | ||
| JP2015501291A5 (enExample) | ||
| NZ734256A (en) | Use of plinabulin in combination with immune checkpoint inhibitors | |
| FI3286223T3 (fi) | Kappa-myelooma-antigeenin kimeerisiä antigeenireseptoreja ja niiden käyttötarkoituksia | |
| JP2020502147A5 (enExample) | ||
| JP2017533207A5 (enExample) | ||
| WO2018132427A1 (en) | Targeted t cells with cytotoxicity toward immunosuppressive cells | |
| JPWO2020104676A5 (enExample) | ||
| CN111867679A (zh) | 用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂 | |
| Sallman et al. | Is disease-specific immunotherapy a potential reality for MDS? | |
| Patel et al. | Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches | |
| Baldan et al. | A dominant negative SHP-2 which abrogates PD-1 signalling pathways and restores function of cytotoxic CAR T cells | |
| Moyal et al. | New therapeutic modalities in breast cancer by targeting NK cell inhibitory and activating receptors | |
| JPWO2020113274A5 (enExample) |